Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical, Inc. (NYSE: GMED) is a global musculoskeletal company in the surgical and medical instrument manufacturing industry. The GMED news page on Stock Titan aggregates coverage focused on the company’s musculoskeletal solutions, enabling technologies, and corporate developments that matter to investors and healthcare professionals.
News about Globus Medical often centers on quarterly and annual financial results, where the company reports worldwide net sales, U.S. and international performance, and non-GAAP metrics such as adjusted EBITDA, non-GAAP net income, and non-GAAP diluted earnings per share. These releases also discuss trends in its U.S. Spine business, contributions from acquisitions such as NuVasive and Nevro, and updates to revenue and earnings guidance.
Product and technology announcements are another key news category. Globus Medical has highlighted launches like the ANTHEM™ Elbow Fracture System within its trauma portfolio and additions to its Power Portfolio, including the DuraPro™ oscillating system with navigation and the Verzera™ high-speed drill system, which integrate with platforms such as ExcelsiusGPS™ and ExcelsiusHub™. These updates provide insight into the company’s efforts to advance spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies.
Investors can also follow corporate and legal developments, including leadership transitions at the executive level, share repurchase authorizations, and patent litigation outcomes related to expandable spinal fusion implants and other technologies. Earnings call schedules and webcast details are regularly announced, giving context on how management views business performance and strategic priorities.
By monitoring GMED news, readers can track how Globus Medical’s financial results, product pipeline, acquisitions, and intellectual property strategy evolve over time. Bookmark this page to access an organized stream of company-specific headlines and updates.
Globus Medical (NYSE: GMED) reported preliminary unaudited sales for Q4 and full year 2025. Q4 2025 sales are estimated at $823.2M, up 25.2% year-over-year on an as-reported basis. Full year 2025 sales are estimated at $2.936B, up 16.5% year-over-year. Excluding Nevro, Globus base business Q4 revenue was $723.3M, up 10.0% year-over-year, led by US Spine. The company issued 2026 revenue guidance of $3.18B–$3.22B and non-GAAP EPS guidance of $4.30–$4.40. Final audited results are expected on Feb 24, 2026.
Globus Medical (NYSE: GMED) reported third quarter 2025 results: worldwide net sales $769.0M (+22.9% / +22.3% constant currency) and GAAP net income $119.0M (+129.5%). GAAP diluted EPS was $0.88 and non-GAAP diluted EPS was $1.18 (+42.6%).
Quarter highlights include U.S. sales +24.6%, international sales +16.5% (13.5% CC), record non-GAAP free cash flow $213.9M (up 24% QoQ), net cash from operations $249.7M, and $40M of share repurchases in Q3 (total repurchases $255.5M YTD).
The company raised 2025 guidance to $2.86–$2.90B revenue and $3.75–$3.85 non-GAAP EPS; Nevro is expected to be accretive in 2025.
Globus Medical (NYSE:GMED) will announce third quarter results for the period ended September 30, 2025 after market close on Thursday, November 6, 2025. A copy of the release will be available on the company Investors website.
After the release, Globus Medical will host a teleconference and live webcast at 4:30 p.m. Eastern Time for the investment community. Telephone participants must register in advance to receive dial-in details, a unique passcode, and registrant ID. An audio archive will be posted on the Investors page after the call.
Globus Medical (NYSE: GMED) launched the ANTHEM™ Elbow Fracture System on October 14, 2025, a comprehensive plating portfolio for a wide spectrum of elbow fractures.
The system includes 14 plate families, 2.7mm and 3.5mm screw options, anatomy-specific reduction instruments, and polyaxial locking holes that permit fixed-angle or 40º cone angulation for flexible fixation. Devices target distal humerus, proximal ulna, proximal radius, and coronoid fractures and are designed to simplify surgical workflow for complex patterns.
Globus Medical (NYSE: GMED) has secured a favorable jury verdict in a patent infringement case against Life Spine, Inc. in Delaware. The jury found that Life Spine's Prolift implants infringed on Globus Medical's patent for expandable spinal fusion implants, awarding both lost profits and reasonable royalty damages.
The company, led by CEO Keith Pfeil, also has a separate ongoing patent litigation against Alphatec, Inc. regarding expandable implant and retractor technology. The verdict reinforces Globus Medical's position as a leading innovator in musculoskeletal technology, particularly in expandable implant technologies that improve spinal surgery outcomes.
Globus Medical (NYSE:GMED) reported strong Q2 2025 financial results with worldwide net sales of $745.3 million, up 18.4% year-over-year. The company achieved GAAP net income of $202.8 million, a remarkable 538.7% increase, largely driven by a $110.6 million bargain purchase gain and a $34.8 million tax benefit.
Key highlights include U.S. net sales growth of 20.3% and international sales growth of 11.0%. The U.S. Spine business showed particular strength, growing 5.7% (7.4% day-adjusted). GAAP diluted EPS reached $1.49, while non-GAAP diluted EPS was $0.86, up 14.1% from Q2 2024.
The company reaffirmed its 2025 guidance, projecting revenue between $2.80-$2.90 billion and non-GAAP EPS of $3.00-$3.30.
Globus Medical (NYSE:GMED) announced significant leadership changes and preliminary Q2 2025 results. Keith Pfeil, former EVP, COO and CFO, has been appointed President and CEO, replacing Daniel Scavilla who resigned to pursue other opportunities. Additionally, Kyle Kline has been promoted to SVP and CFO.
The company reported preliminary Q2 2025 sales of $745.3 million, an 18.4% increase year-over-year. Base business sales, excluding Nevro Inc. acquisition, reached $650.8 million, growing 3.3% as reported and 4.8% on a day-adjusted basis. The US Spine business showed strong performance with 7.4% growth on a day-adjusted basis.
Globus Medical reaffirmed its full-year 2025 guidance with revenue expected between $2.80-$2.90 billion and non-GAAP EPS of $3.00-$3.30.
Globus Medical (NYSE:GMED), a leading musculoskeletal technology company, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results with investors. Participants can join via webcast through the company's investor relations website or by telephone through pre-registration. The audio recording will be available after the call on the company's investor website.
Globus Medical (NYSE: GMED) has unveiled DuraPro™, a next-generation oscillating system with enhanced navigation capabilities through its Excelsius™ platform. The system aims to disrupt the $550 million high-speed drill market with innovative technology designed to protect delicate tissue during surgical procedures.
DuraPro™'s key features include anti-skiving pilot hole drilling, brush attachments for thorough discectomies, and seamless integration with ExcelsiusGPS™ and ExcelsiusHub™. The company also launched Verzera™, a navigated high-speed drill system, expanding their Power Portfolio of surgical solutions.
Globus Medical (NYSE: GMED) has announced a significant $500 million share repurchase program of its outstanding common stock. The company's management believes there is a disconnect between their intrinsic value and current market valuation due to recent share price volatility.
The program will be funded through cash reserves and has no time limit. The actual implementation will be at management's discretion, considering factors such as market price, business conditions, legal requirements, and alternative investment opportunities. The repurchases may be executed through private negotiations or open market transactions, including under Rule 10b5-1 and Rule 10b-18.
FAQ
What is the current stock price of Globus Med (GMED)?
What is the market cap of Globus Med (GMED)?
